IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/541,522 Confirmation No.: Unknown

Applicant: Brown et al. PCT Appl. No.: PCT/GB2004/000099

National Phase Fld (371): July 7, 2005 PCT Filed: January 13, 2004

Docket No.: 100952-1P US TC/A.U.: Unknown

Customer No.:22466 Examiner: Unknown

Title: Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO/SB/08A and 08B forms.

Applicants also wish to make the Examiner aware of co-pending applications:

10/477851, a PCT national phase filed on May 16, 2002;

10/477854, a PCT national phase filed on May 16, 2002;

10/477641, a PCT national phase filed on May 16, 2002;

10/477821, a PCT national phase filed on May 16, 2002;

10/240114, a PCT national phase filed on March 30, 2001;

10/240038, a PCT national phase filed on March 30, 2001;

10/222990, filed on August 19, 2002;

10/541664, a PCT national phase filed on January 13, 2004; and

10/541656, a PCT national phase filed on January 13, 2004.

Appl. No. 10/541,522

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).

Respectfully submitted,

Jianzhong Shen

Reg. No.48,076 302-886-8854

Dated: October 17, 2005

Enclosures: Transmittal Form

Forms PTO/SB/08A & 08B

References (13)

Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

Substitute for form 1449/PTO

Sheet 1

STATEMENT BY APPLICANT (Use as many sheets as necessary)

of 3

Complete if Known					
Application Number	10/541,522				
Filing Date	July 7, 2005				
First Named Inventor	William Brown				
Art Unit	Unknown				
Examiner Name	Unknown				
Attorney Docket Number	100052-1P US				

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (# known)}			rigules Appeal
		^{US-} 2,898,339	08/04/1959	Wheeler et al.	
		^{US-} 4,581,171	04/08/1986	Kennis et al.	
		^{US-} 4,816,586	03/28/1989	Portoghese	
		^{US-} 4,939,137	07/03/1990	Russell et al.	
		^{US-} 5,140,029	08/18/1992	Kennis et al.	
		^{US-} 5,574,159	11/12/1996	Chang et al.	
		^{US-} 5,683,998	11/04/1997	Shibayama et al.	
		^{US-} 6,187,792	02/13/2001	Delorme et al.	-
		^{US-} 6,455,545	09/24/2002	Delorme et al.	
		^{US-} 6,552,036	04/22/2003	Boyd et al.	
		^{US-} 6,556,387	04/29/2003	Misso et al.	
		^{US-} 6,756,387	06/29/2004	Brown et al.	
		US-			
,		US-			
		US-		ì	

		FOREIGN	PATENT DOCL	IMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO 93/15062	08/05/1993	The Wellcome Foundation		
		WO 97/23466	07/03/1997	Astra Aktiebolag		
		WO 98/28275	07/02/1998	Astra Pharma, Inc.		
		WO 99/33806	07/08/1999	Ortho-McNeil Pharmaceutic		
		WO 01/74804	10/11/2001	AstraZeneca AB		
		WO 01/74806	10/11/2001	AstraZeneca AB		

Examiner		Date	
Signature		Consider	ed i
	1		l .

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2	of 3	

Complete if Known				
Application Number	10/541,522			
Filing Date	July 7, 2005			
First Named Inventor	William Brown			
Art Unit	Unknown			
Examiner Name	Unknown			
Attorney Docket Number	100952-1P US			

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-	 		
		03-			
		US-			
	_	US-			
-	-	US-			
		US-			
	-	US-			
	<u> </u>	US-			
		US-	†		

Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	Γ
Initials*	No.¹	Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Or Relevant Figures Appear	ו
		WO 02/094786	11/28/2002	AstraZeneca AB		
						Γ
						r

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Office, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
as collection of information unless it contains a valid OMB control number.

Substitu	Substitute for form 1449/PTO			Complete if Known	
Substitute for form 1445/1110		Application Number	10/541,522		
INF	ORMATION	DIS	CLOSURE	Filing Date	July 7, 2005
STA	STATEMENT BY APPLICANT			First Named Inventor	William Brown
	(Use as many sheets as necessary)			Art Unit	Unknown
		013 03 11		Examiner Name	Unknown
Sheet	3	of	3	Attorney Docket Number	100952-1P US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BARBER, A. et al., "Antinociceptive effects of the 5-HT2 Antagonist Ritanserin in Rats: Evidence in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, p. 234-238	
		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, p. 359-366	
		GREENE, T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, p. 218, 220, 232, 233, 251	
		TAKEMORI, A.E. et al., "Selective Natrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, p. 239-269	
		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: A Noveland its Analogues," J. Med. Chem., 2000, Vol. 43, p. 3895-3905	
		ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, p. 5455-5463	
		·	
		-	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OCT 1 9 2005

2017 200**7** 1 9 00T 200**7**

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
twork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. THE HAPE Application Number 10/541,522 TRANSMITTAL Filing Date July 7, 2005 First Named Inventor **FORM** Brown Art Unit Unknown **Examiner Name** Unknown (to be used for all correspondence after initial filing) Attorney Docket Number 100952-1P US Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information After Final Provisional Application Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer **Extension of Time Request** below): Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Signature Printed name Jianzhong Shen Date Reg. No. 48,076 October 17, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date October 17, 2005 Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

AstraZeneca Docket No. 100492-1P US

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of:

BROWN, William et al.

US Application No:

Not Yet Assigned

US Application Filed:

PCT Application No:

PCT/SE02/01804

PCT Filed:

October 2, 2002

For: 4[Piperidin-4-Yliden-(3-Carbamoylphenyl)Methyl]Benzamide Derivatives and Their Use for the Treatment of Pain, Spinal Injuries or Gastrointestinal Disorders

Examiner: Not yet allocated Group Art Unit: Not yet allocated

Mail Stop PCT Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Appicants also wish to make the Examiner aware of co-pending applications:

10/477851, a PCT national phase filed on May 16, 2002; 10/477854, a PCT national phase filed on May 16, 2002; 10/477641, a PCT national phase filed on May 16, 2002; 10/477821, a PCT national phase filed on May 16, 2002; 10/477821, a PCT national phase filed on May 16, 2002; 10/240114, a PCT national phase filed on March 30, 2001; 10/240038, a PCT national phase filed on March 30, 2001; and 10/222990, filed on August 19, 2002.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed together with the filing under 35 U.S.C. § 371 of the national stage of an international application and hence no fee is required for consideration of the references. However, the Examiner is authorized to charge any fees that may be due to Deposit Account No. 260166.

Respectfully submitted,

Dated: March 30, 2004

Jianzhong Shen Agent for Applicants Reg. No. 48,076

Telephone: 302/886-8854

PTO/SB/08a (05-03)

Approved for use through 04/30/2003, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number Not Yet Assigned Filing Date First Named Inventor William Brown, et al. Art Unit Not Yet Assigned Examiner Name Not Yet Assigned

(Use as many sheets as necessary Sheet of **Attorney Docket Number** 100492-1P US

			U. S. PATENT I	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (Tanom)}	Publication Data MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Al	^{US-} 2,898,339	Aug. 4, 1959	Wheeler, et al.	
	A2	^{US-} 4.581.171	April 8, 1986	Kennis, et al.	
	A3	^{US-} 4,816,586	March 28, 1989	Portoghese	
	A4	^{US-} 4,939,137	July 3, 1990	Russell, et al.	
	A5	^{US-} 5,140,029	Aug. 18, 1992	Kennis, et al.	
	A6	us- 5,574,159	Nov. 12, 1996	Chang, et al.	
	A7	^{US-} 5,683,998	Nov. 4, 1997	Shibayama, et al.	
	A8	^{US-} 6,187,792	Feb. 13, 2001	Delorme, et al.	
	A9	US- 6,455,545 US-	Sept., 24, 2002	Delorme, et al.	
		US-	· · · · · · · · · · · · · · · · · · ·		
		US-			

	FOREIGN PATENT DOCUMENTS								
	Cite	Dite Foreign Patent Document		Publication Date	Name of Patentee or	Pages, Columns, Lines,			
Inilia!s*	Initials* No.1	Cour≐ry Code	3-Number 4-Kind Code ⁵ (3 Irrain)	YGT-DD-AAAA	Applicant of Cited Document	Where Relevant Pessages or Relevant Figures Appear	Τ ^S		
	B1	wo	99/33806	July 8, 1999	Ortho-McNeil Pharmaceutical, Inc.				
	B2	wo	93/15062	Aug. 5, 1993	The Wellcome Foundation Ltd.				
	B3	wo	97/23466	July 3, 1997	Astra Aktiebolag				
	B4	wo	98/28275	July 2, 1998	Astra Pharma, Inc.				
	B5	wo	0174804	Oct. 11, 2001	AstraZeneca AB				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not *EXAMINER: in all in relierance considered, whether of not cluston is in continuous with kin22" out. Draw time through channon in not in conformance and not considered, Indiude copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See kinds Codes of USPTO Patent Documents at www.uspto.gog or hiPEP 901.04. There office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fite (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. ON/8 0651-0031
U.S. Palent and Tredemark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO **Application Number** Not Yet Assigned Filing Date INFORMATION DISCLOSURE First Named Inventor STATEMENT BY APPLICANT <u>William Brown, et al</u> Art Unit Not Yet Assigned **Examiner Name** Not Yet Assigned (Use as many sheets as necessary **Attomey Docket Number** Sheet of 100492-1P US 2 U. S. PATENT DOCUMENTS Cite No.1 **Document Number** Publication Date
AULI-DD-YYYY Name of Patentee or Examiner Peges, Columns, Lines, Where Applicant of Cited Document Initials* Relevant Passages or Relevant Number-Kind Code^{2 (# known)} Figures Appear US. US US. US-US-US-US-US-US US-US-US-US-IIS-US-US US-US FOREIGN PATENT DOCUMENTS Publication Date Foreign Patent Document Name of Patentee or Examiner eges, Columns, Lines, Where Relevant Passages Applicant of Cited Document Initials* Country Code 3 Number 4-Kind Code 5 (# этомп) or Relevant Figures Appear 0174806 Oct. 11, 2001 AstraZeneca AB **B**6 WO Date Examiner Considered Signature

"Examined invaring relatence considered, whether or not classon is in contomisined with NPEP 609, Oraw the subogn classon it not in contomisined and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.us.edo.gov, or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gethering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petentand and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO	_	Complete If Known		
	Application Number	Not Yet Assigned		
INFORMATION DISCLOSURE	Filing Date			
STATEMENT BY APPLICANT	First Named Inventor	William Brown et al.		
files on many phases as massacra?	Art Unit	Not Yet Assigned		
(Use as many sheets as necessary)	Examiner Name	Not Yet Assigned		
Sheet 1 of 1	Attorney Docket Number			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	Cı	Bilsky, et al., "SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist, J. Pharmacol. Experi. Ther. 273:359-366(1995)	
	C2	Takemori, et al., "Selective Natrexone-Drived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).	
	СЗ	Barber, et al., "Antinociceptive Effects of the 5-HT Antagonist Ritanserin in Rats: Evidence for an Activation in the Spinal Cord," Neuroscience Letters 99:234-238 (1989).	
	C4	Greene, "Protective Groups in Organic Synthesis," Wiley & sons, pp. 218, 220, 232, 233, 251 (1982).	
	C5	Wei, et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl) and its Analogues," J. Med. Chem. 43:3895-3905 (2000).	
	C6	Zhang, et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis Opioid Receptor Ligands," J. Med. Chem. 42:5455-5463 (1999).	
		·	

Examiner Signature	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

[&]quot;EXAMINER: Initial if reference considered, whether or not criation is in conformance with MPEP 609. Draw tire through criation in not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique criation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of Information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application of:

BROWN, William et al.

US Application No:

10/477821

US Application Filed:

November 13, 2003

PCT Application No:

PCT/SE02/00953

PCT Filed:

May 16, 2002

For:

4-(Phenyl-Piperidin-4-Ylidene-Methyl)-Benzamide Derivatives and Their use for the Treatment of Pain,

Anxiety or Gastrointestinal Disorders

Examiner: Not yet allocated Group Art Unit: Not yet allocated

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

Applicants also wish to make the Examiner aware of co-pending applications:

10/3/2 8 10/477851, a PCT national phase filed on May 16, 2002; 10/477854, a PCT national phase filed on May 16, 2002; 10/477641, a PCT national phase filed on May 16, 2002; 10/240114, a PCT national phase filed on March 30, 2001; 10/240038, a PCT national phase filed on March 30, 2001; and 10/270-3 10/222990, filed on August 19, 2002.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

This Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits; and hence no fee is required for consideration of the references. However, the Examiner is authorized to charge any fees that may be due to Deposit Account No. 260166.

Respectfully submitted,

Dated: February /8, 2004

Jianzhong Shen
Agent for Applicants

Reg. No. 48,076

Telephone: 302/886-8854

PTO/SB/08a (05-03)

Approved for use through 04/30/2003, OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to re		mark Office; U.S. DEPARTMENT OF COMMERCE tion unless it contains a valid OMB control number.	
Substitute for form 1449A/PTO	Complete if Known		
	Application Number	10/477821	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

UŞ-ÜS- of

Filing Date November 13, 2003 First Named Inventor William Brown, et al Examiner Name

Attorney Docket Number | 100367-1P US Sheet **U. S. PATENT DOCUMENTS** Cite No. Name of Patentee or Examiner **Document Number Publication Date** Pages, Columns, Lines, Where Relevant Passages or Relevant Initials* NULL DD-YYYY Applicant of Cited Document Number-Kind Code² (Firment) Figures Appear US-Aug. 4, 1959 Wheeler, et al. A1 2,898,339 US-A2 4,581,171 April 8, 1986 Kennis, et al. 4,816,586 March 28, 1989 | Portoghese Α3 July 3, 1990 4,939,137 Russell, et al. A4 US-Aug. 18, 1992 Kennis, et al. A5 5,140,029 US-Nov. 12, 1996 Chang, et al. А6 5,574,159 Nov. 4, 1997 A7 5,683,998-Shibayama, et al. Feb. 13, 2001 Delorme, et al. 6,187,792 A8 บร-**A9** 6,455,545 Sept., 24, 2002 Delorme, et al. US-US-US-US US-US-IIS-

	FOREIGN PATENT DOCUMENTS									
Exeminer Initials*	Cite No.	Foreign Patent Document Country Code ³ Number ⁴ -Kind Code ⁵ (# Immun)		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	To			
	B1	WO	99/33806	J	July 8, 1999	Onho-McNeil Pharmaceutical, Inc.	•			
	B2	wo	93/15062	J,	Aug. 5, 1993	The Wellcome Foundation Ltd.				
	B3	wo J	97/23466	J,	July 3, 1997	Astra Aktiebolag				
	В4	wo J	98/28275		July 2, 1998	Astra Pharma, Inc.				
	B5	WO	0174804	3	Oct. 11, 2001	AstraZeneca AB				

Examiner Signature	Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional), ² See Kinds Codes of USPTO Patent Documents at www.usplo.gog/ or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Jepanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fits (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burdon, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/\$B/08a (05-03)

Approved for use through 04/30/2003. 0/4/9 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	Substitute for form 1449A/PTO			Complete if Known		
				Application Number	10/477821	
INF	ORMATION DISC	CLO	SURE	Filing Date	November 13, 2003	
	ATEMENT BY AF			First Named Inventor	William Brown, et al.	
•		-		Art Unit		
	(Use as many sheets as nec	ess <i>ar</i> v)	Examiner Name		
Sheet	9	of	a	Attorney Docket Number	100367-1P US	

Examiner (Cite No.	Document Number	U. S. PATENT I Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
iniuais	180.	Number-Kind Code ^{2 (Firmen)}	KINPOD-1111	Applicant of cited occurrent	Figures Appear	
		US-				
		US-				
		US-				
-		US-	***************************************			
		US-				
		US-				
		US-				
	 	US-				
		US-				
	i –	US-				
		US-				
		US-				
_		US-				
		US-		,		
	1	US-				
	1	US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.		ent Document Thurser ⁴ Kind Code ⁵ (# known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	16	
	В6	WO	0174806	Oct. 11, 2001	AstraZeneca AB			
_								

Examiner Signature	 Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or kIPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTC/SB/08b(05-03)
Approved for use through 04/30/2003. Ok/9 0651-0031
U.S. Palant and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for	r form 1449B/PTO			Complete if Known			
WEO				Application Number	10/477821		
	RMATION DI			Filing Date	November 13, 2003		
SIAI	EMENT BY	APPLIC	CANT	First Named Inventor	William Brown et al.		
				Art Unit			
	(Use as many sheets as	necessary)		Examiner Name			
Sheet	1	of	1	Attorney Docket Number	100367-1P US		

		NON PATENT LITERATURE DOCUMENTS	٦
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
1	.C1	Bilsky, et al., "SNC 80, A Selective, Nonpeptidic and Systemically Active Opioid Delta Agonist, J. Pharmacol. Experi. Ther. 273:359-366(1995)	
	C2	Takemori, et al., "Selective Natrexone-Drived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol. 32:239-269 (1992).	
J	С3	Barber, et al., "Antinociceptive Effects of the 5-HT Antagonist Ritanserin in Rats: Evidence for an Activation in the Spinal Cord," Neuroscience Letters 99:234-238 (1989).	
1	C4	Greene, "Protective Groups in Organic Synthesis," Wiley & sons, pp. 218, 220, 232, 233, 251 (1982).	
	C5	Wei, et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl) and its Analogues," J. Med. Chem. 43:3895-3905 (2000).	
	C6	Zhang, et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis Opioid Receptor Ligands," J. Med. Chem. 42:5455-5463 (1999).	
			7

					_
Examiner		i	Date	i	
Signature			Considered	j	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including to process) an application. Controlled by 59 U.S.C. 122 and 37 CFR 1.14. This confection is estimated to take 120 minutes to complete, including gathering, and submitting the completed application form to the USPTO. Time will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

	~~~			Application 10/477,82	n/Control No.		Applicant(s) Reexaminat WEI ET AL.	/Palei ion	nt Under
		Notice of References	s Cited		Examiner		Art Unit		
				Rita J. De			1625		Page 1 of 1
ىم سى				U.S. PATENT DOC				÷	
*		Document Number	Dale MM-YYYY		Name		<del></del>		Classification
 X	l	US-6,756,387 6,756,387		Brown et al.				<del>                                     </del>	514/318
			09-2002	Delorme et al.	29-04	D 0101	di estat	2	
<u>X.</u>	Ð	US 6 553 036	03-2002	Delorme et al. 9-24-02 already Cital  Boyd et al. 4-22-03				514/299	
<u>X</u>	C	US-6,652,0366,552,036	D-1-2003	Boyd et al.	9-00	-0.5	<del> </del>		017/200
	D	US-	·						<del></del>
	E	US-							
	F	US-		ļ					
	<u>'</u> G	us: ·				<del></del>	· 	<u>                                     </u>	
	Н	US-			·				· · · · · · · · · · · · · · · · · · ·
		US-			·	· ——————	·,	-	
	٤	US-		•			· ·:	1:	
	K	US-					·	<u> </u>	٠, (
	l.	UŞ-						<u>L'</u>	
	М	US-							
	~~~			FOREIGN PATENT D	OCUMENTS	-		<b>~~~~</b>	
*		Document Number Country Code Number Kind Code	Dalo MM-YYYY	Country		Name			Classification
X	N	WCOC12027598/28275	07-1998	workendy city	d Delorme D	.et ଲା		<u> </u>	
	0	,							
	þ								
	a	MANAGE CONTRACTOR OF THE PARTY							
	R			· · · · · · · · · · · · · · · · · · ·					
	S					-		 	
~~·	`T	:			<u> </u>	· ;, ·	,	-	:,
,1		I и туму могу шки зачениминими стиницим груп		NON-PATENT DOC					
*		Includ	le us applicable	: Author, Title Date, Po	ıblisher, Edition o	r Volume, P	ertinent Pages)	
X	u	Wei et al. N.N diathyl-1 (pheny	rlpiperidlne 4	-viidenemethyl0benz	amide J. Of N	1 /	. 2000, Vol, 4	3, 38	95-3905.
						min	ستقع	OC.	
	٧				. •		:	; ;	•
	w					, - 			
	X		<i></i>					` ,	

US Polost and Tendemark Office PTO-802 (Rev. 01-2001)

Notice of References Cited

Part of Paper No. 20050610

	Notice of Reference	s Cited			
	Monce of Veteralice	g Uniou	Examiner Rita J. Desal	Art Unit 1625	Page 1 of 1
			U.S. PATENT DOCUMENTS		
*	Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	9	Classification
A	US-6,556,387	04-2003	Misso et al.		360/265.6
В	US-				
С	US-				
D	US- +.4:	×			
Ε	US-				
F	US-				
G	US-				
Н	US-				
	US-				
J	U\$-				
к	US-				
L	US-				
М	US-				
			FOREIGN PATENT DOCUMENTS		
*	Document Number - Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
N	·				
0					
Р		<u> </u>			
Q		<u> </u>			
R		1	l I		
		<u> </u>			
s	4.3				
					
S			NON-PATENT DOCUMENTS		
s		de as applicabl	NON-PATENT DOCUMENTS e: Author, Title Date, Publisher, Edit	ilon or Volume, Pertinent Pages)	·
S	İnclu	de as applicabl		ion or Volume, Pertinent Pages)	•
* T	İnclu	de as applicabl		ion or Volume, Pertinent Pages)	
* T	İnclu	de as applicabl		ion or Volume, Pertinent Pages)	
* U	indu	de as applicabl		ion or Volume, Pertinent Pages)	
* U	indu	de as applicabl		lon or Volume, Pertinent Pages)	·
* U	inclu	de as applicabl		ion or Volume, Pertinent Pages)	

Notice of References Cited

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

.

· · · ·

Application/Control No.

10/477,821

Applicant(s)/Patent Under Reexamination WEI ET AL.

Part of Paper No. 20041110